Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed?

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...
Forbes

What's Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Business Wire

Dr. Imran S. Haque, Biology Machine Learning Expert, Joins Recursion as VP of Data Science

SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...
Business Wire

Splunk Machine Learning Helps Recursion Pharmaceuticals Treat Genetic Diseases

SAN FRANCISCO--(BUSINESS WIRE)--Splunk Inc. (NASDAQ: SPLK), first in delivering “aha” moments from machine data, today announced biotechnology company Recursion Pharmaceuticals is using Splunk® ...